- Home
- GITS vs CDIO Comparison
GITS vs CDIO Comparison
Compare GITS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- CDIO
- Stock Information
- Founded
- GITS 2018
- CDIO 2017
- Country
- GITS South Korea
- CDIO United States
- Employees
- GITS N/A
- CDIO N/A
- Industry
- GITS
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- GITS
- CDIO Health Care
- Exchange
- GITS Nasdaq
- CDIO Nasdaq
- Market Cap
- GITS 5.7M
- CDIO 6.8M
- IPO Year
- GITS N/A
- CDIO N/A
- Fundamental
- Price
- GITS $1.51
- CDIO $3.95
- Analyst Decision
- GITS
- CDIO
- Analyst Count
- GITS 0
- CDIO 0
- Target Price
- GITS N/A
- CDIO N/A
- AVG Volume (30 Days)
- GITS 191.8K
- CDIO 32.6K
- Earning Date
- GITS 11-14-2025
- CDIO 11-14-2025
- Dividend Yield
- GITS N/A
- CDIO N/A
- EPS Growth
- GITS N/A
- CDIO N/A
- EPS
- GITS N/A
- CDIO N/A
- Revenue
- GITS $29.00
- CDIO $19,507.00
- Revenue This Year
- GITS N/A
- CDIO $1,434.82
- Revenue Next Year
- GITS N/A
- CDIO $4,661.91
- P/E Ratio
- GITS N/A
- CDIO N/A
- Revenue Growth
- GITS N/A
- CDIO N/A
- 52 Week Low
- GITS $0.87
- CDIO $3.22
- 52 Week High
- GITS $9.78
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- GITS 32.24
- CDIO 43.29
- Support Level
- GITS $1.55
- CDIO $3.70
- Resistance Level
- GITS $1.68
- CDIO $3.99
- Average True Range (ATR)
- GITS 0.11
- CDIO 0.30
- MACD
- GITS -0.01
- CDIO -0.04
- Stochastic Oscillator
- GITS 8.62
- CDIO 16.67
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.